$1.35
0.021.5%
Last update: Nov 12, 7:34 AM
NervGen Pharma Corp
NGENNASDAQ
NervGen Pharma fell 77.4% from $5.97 to $1.35, behind the S&P 500's +10.2%. Its worst day was May 22 (−43.5%), and its low came Nov 3 at $1.32.
Jan 8, 2026 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
NervGen Pharma shares rose 15.6%, while the S&P 500 rose 0.8%.
+15.6%, the year's best day · S&P 500 +0.8%
The offering is being made pursuant to a prospectus supplement to an amended and restated short form base shelf prospectus dated December 15, 2025 (the "Base Shelf Prospectus") filed in all of the provinces and
Story events cover the past 12 months · Times ET
−43.5%, the year's worst day, on 12M shares, the year's heaviest volume · S&P 500 +0.4%
EPS of $-0.27 was reported on $0.00 revenue.
0.0% · S&P 500 +0.7%
NervGen Pharma closed at its lowest level of the year, 77.9% below where the year started.
−2.2% · S&P 500 +0.3%
Where it ended: a close of $1.35 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 23, 2026 (EPS est. $0.01).
Nothing in the past 12 months.
All NGEN dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NGEN and SPY from Benzinga historical bars. Not investment advice.
